PrevEp-004 is under clinical development by PrevEp and currently in Phase I for Status Epilepticus. According to GlobalData, Phase I drugs for Status Epilepticus have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PrevEp-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PrevEp-004 is under development for the treatment of drug resistant status epilepticus.
PrevEp biotech company focused in the epilepsy research and development of new therapies for epilepsy prevention. PrevEp is headquartered in Bethesda, Maryland, the US.
For a complete picture of PrevEp-004’s drug-specific PTSR and LoA scores, buy the report here.